Related Experiment Video
Updated: Oct 4, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Application of apatinib after multifaceted therapies for metastatic breast cancer
Jue Wang1, Yangyang Chen1, Renwang Chen1
1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background:
Apatinib is a small molecule tyrosine kinase inhibitor (TKI) that is taken orally and has high specificity for vascular endothelial growth factor receptor 2 (VEGFR-2). This study explored the efficacy and toxicity of apatinib in patients with metastatic breast cancer (MBC) who failed to respond to multifaceted therapy.
Methods:
A total of 61 patients with MBC who were unresponsive to previous multifaceted chemotherapy were included in this study. The treatment regimens were either a combination of apatinib and chemotherapy or apatinib administered singly with a dose range of 250 mg every second day to 500 mg per day. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and toxicity were used as outcome measures.
Results:
Of the 61 patients, partial response (PR) was observed in 14 patients (23.0%), stable disease (SD) was observed in 30 patients (49.2%), and progressive disease (PD) was observed in 17 patients (27.8%). The DCR was 44/61 (72.1%), and the ORR was 14/61 (23.0%). Of the 44 patients who achieved PR or SD, the median PFS was 4 months and 15 days. Patients with intracranial metastases were found to benefit from apatinib. Furthermore, 11 patients underwent next generation sequencing (NGS) and 5 of these had a P53 mutation. Of those 5 cases, the ORR and DCR were 0% and 20.0%, respectively. Of the 6 cases with wild-type P53, the ORR was 50.0%, and the DCR was 100.0%. Multivariate regression analysis found that hypertension was an independent prognostic factor of better DCR.
Conclusions:
Apatinib showed good efficacy and manageable toxicity in patients with MBC that had not responded to multifaceted therapy.
Insights
Apatinib demonstrated efficacy in patients with metastatic breast cancer (MBC) resistant to prior treatments. This oral tyrosine kinase inhibitor showed manageable toxicity and a notable disease control rate in the studied population.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Apatinib is an oral small molecule tyrosine kinase inhibitor targeting VEGFR-2.
- Investigated apatinib's efficacy and toxicity in metastatic breast cancer (MBC) patients with prior treatment failure.
Purpose of the Study:
- To evaluate apatinib's effectiveness and safety in refractory MBC patients.
- To determine progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).
Main Methods:
- 61 MBC patients unresponsive to prior chemotherapy were enrolled.
- Treatment involved apatinib monotherapy or combination therapy at varying doses.
- Outcome measures included PFS, ORR, DCR, and toxicity assessment.
Main Results:
- Disease control rate (DCR) was 72.1% (44/61), with an objective response rate (ORR) of 23.0% (14/61).
- Median PFS was 4 months and 15 days for patients achieving partial response or stable disease.
- Apatinib showed potential benefit in patients with intracranial metastases and wild-type P53.
- Hypertension emerged as an independent prognostic factor for better DCR.
Conclusions:
- Apatinib exhibits favorable efficacy in MBC patients resistant to multifaceted therapy.
- The treatment is associated with manageable toxicity profiles.
- Further research into P53 mutations and hypertension as prognostic factors is warranted.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
10:33Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers